Which biotech was a 37-bagger?
News & Analysis: NeoGenomics, Inc.
These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.
Helping people stricken with illness can be richly rewarding in more ways than one.
The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along.
An excellent third-quarter performance for the genetic testing company has investors cheering.
NEO earnings call for the period ending September 30, 2019.
These stocks have track records of success and plenty of growth ahead.
Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
It was a great month to be a genetic testing company.
NEO earnings call for the period ending July 30, 2019.